- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | Meihua International wechselt zum Nasdaq Capital Market für Compliance | - | Investing.com Deutsch | ||
| 06.06. | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.04. | Meihua GAAP EPS of $0.40, revenue of $96.91M | 1 | Seeking Alpha | ||
| 25.04. | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 25.04. | Meihua International Medical Technologies Co., Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.04. | Meihua International Medical Technologies Co., Ltd. Full Year Income Retreats | 260 | AFX News | BEIJING (dpa-AFX) - Meihua International Medical Technologies Co., Ltd. (MHUA) released a profit for full year that decreased from the same period last yearThe company's bottom line came in... ► Artikel lesen | |
| 25.04. | Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results | 114 | PR Newswire | YANGZHOU, China, April 25, 2025 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer... ► Artikel lesen | |
| 20.09.24 | Meihua International Medical Technologies Co., Ltd.: Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results | 250 | PR Newswire | YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II... ► Artikel lesen | |
| 31.07.24 | Pre-market Movers: NuZee, Imunon, Meihua International Medical Technologies, Powell Industries, MacroGenics | 894 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.40 A.M. ET).In the Green NuZee, Inc. (NUZE) is up over 51% at $5.60.
Meihua... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,093 | -2,62 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,715 | +2,00 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,956 | -1,65 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand | HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was held in Shanghai. Ping An Healthcare and... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,238 | -0,83 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,917 | +3,38 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
| VERU | 0,501 | -2,15 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| VOLITIONRX | 0,756 | 0,00 % | VolitionRx - Nu.Q advances in lung cancer management | Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading... ► Artikel lesen | |
| EKSO BIONICS | 3,480 | +6,10 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| IMUNON | 0,680 | -1,45 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
| BEYOND AIR | 0,155 | +2,65 % | Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and... ► Artikel lesen | |
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,477 | +6,00 % | Novacyt S.A. - Liquidity Agreement Monthly Update and TVR | ||
| AROVELLA THERAPEUTICS | 0,047 | -3,09 % | AROVELLA THERAPEUTICS LIMITED: Notification of cessation of securities - ALA | ||
| SIEMENS HEALTHINEERS | 46,170 | -1,20 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
Das Unternehmen MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,425 Euro und damit +1,19 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD finden Sie auf Wallstreet Online.